Topics

REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich’s Ataxia Using NAV AAV9 Vector

09:52 EDT 2 Aug 2019 | Speciality Pharma Journal

ROCKVILLE, Md., July 31, 2019 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc. Under the terms of the agreement, REGENXBIO has granted Pfizer …

Original Article: REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich’s Ataxia Using NAV AAV9 Vector

NEXT ARTICLE

More From BioPortfolio on "REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich’s Ataxia Using NAV AAV9 Vector"

Quick Search

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...